Company: MLTX
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001821586-25-000022
Chunk: 1

Company: MoonLake Immunotherapeutics
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 1
Chunk 1
---
audited)

Three Months Ended September 30, Nine Months Ended September 30, (in thousands, except share and per share data)2025202420252024Operating expensesResearch and development$(60,635)$(35,736)$(146,856)$(72,412)General and administrative(10,799)(7,376)(32,760)(21,099)Total operating expenses(71,434)(43,112)(179,616)(93,511)Operating loss(71,434)(43,112)(179,616)(93,511)Interest expense(3,198)—(5,254)—Other income, net4,0537,09017,93018,903Loss before income tax(70,579)(36,022)(166,940)(74,608)Income tax expense(115)(92)(363)(241)Net loss$(70,694)$(36,114)$(167,303)$(74,849)Of which: net loss attributable to controlling interests shareholders(69,729)(35,390)(164,891)(73,331)Of which: net loss attributable to noncontrolling interests shareholders(965)(724)(2,412)(1,518)Net unrealized gain (loss) on marketable securities and short-term investments(255)(325)(4,920)509Actuarial gain (loss) on employee benefit plans8(116)116(111)Other comprehensive income (loss)(247)(441)(4,804)398Comprehensive loss$(70,941)$(36,555)$(172,107)$(74,451)Comprehensive loss attributable to controlling interests shareholders(69,972)(35,823)(169,622)(72,941)Comprehensive loss attributable to noncontrolling interests(969)(733)(2,485)(1,510)Weighted-average number of Class A Ordinary Shares, basic and diluted63,369,98462,896,78263,295,99962,803,220Basic and diluted net loss per share attributable to controlling interests shareholders$(1.10)$(0.56)$(2.61)$(1.17) 

The accompanying Notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.    

3

MOONLAKE IMMUNOTHERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY(Unaudited)

Class A Ordinary SharesClass C Ordinary SharesAdditional Paid-In